Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Gilead sciences, inc. symbols : Alny save search
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.49 480K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.825 -0.34% 9.7M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $168.21 -0.78% 1.2M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.615 -2.25% 730K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.03 2.4M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $144.52 -1.06% 140K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
Published: 2022-06-25 (Crawled : 12:20) - globenewswire.com
GILD | $67.03 2.4M
|
Health Technology
| Email alert
Add to watchlist
VIR | $8.205 0.92% 240K
|
Health Technology
| Email alert
Add to watchlist
ALNY | $144.52 -1.06% 140K
|
Health Technology
| Email alert
Add to watchlist
hepatitis program
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-24 (Crawled : 01:00) - biospace.com/
VIR | $8.205 0.92% 240K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
GILD | $67.03 2.4M
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
ALNY | $144.52 -1.06% 140K
|
Health Technology
|
| O: -2.95%
H: 0.0%
C: 0.0%
financial results technology report results biotech iot
Global Gene Therapy Market Report 2021: Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
Published: 2021-07-13 (Crawled : 11:00) - prnewswire.com
QURE | $4.585 -3.47% 280K
|
Health Technology
|
| O: -0.64%
H: 1.28%
C: -1.0%
SRPT | $117.81 0.59% 220K
|
Health Technology
|
| O: -0.88%
H: 1.98%
C: -1.13%
SGMO | News | $0.4922 -5.51% 700K
|
Health Technology
|
| O: -0.49%
H: 1.63%
C: 0.0%
RGNX | $15.75 -0.94% 120K
|
Health Technology
|
| O: -0.51%
H: 0.95%
C: -1.06%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 0.05%
H: 0.22%
C: -4.26%
NTLA | $21.1 -2.0% 360K
|
Health Technology
|
| O: -0.48%
H: 1.36%
C: -2.65%
GILD | $67.03 2.4M
|
Health Technology
|
| O: -0.35%
H: 1.01%
C: 0.27%
EDIT | News | $5.375 -1.56% 590K
|
Health Technology
|
| O: -0.15%
H: 1.2%
C: -4.78%
CRSP | News M | $56.02 -0.69% 390K
|
Health Technology
|
| O: -0.47%
H: 0.76%
C: -3.24%
BLUE | $0.9227 -4.94% 4.6M
|
Health Technology
|
| O: -0.7%
H: 0.95%
C: -2.43%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: -2.09%
ALNY | $144.52 -1.06% 140K
|
Health Technology
|
| O: -0.56%
H: 1.51%
C: -0.23%
ADAP | $1.095 -3.95% 540K
|
Health Technology
|
| O: -0.25%
H: 0.25%
C: -1.78%
ABEO | News | $3.195 -6.31% 1.4M
|
Health Technology
|
| O: 2.11%
H: 0.0%
C: -4.83%
gene therapy therapy gene therapies
Global Gene Therapy Market to Reach $2.7 Billion by 2026
Published: 2021-06-29 (Crawled : 14:15) - prnewswire.com
QURE | $4.585 -3.47% 280K
|
Health Technology
|
| O: 0.1%
H: 1.22%
C: -0.26%
SRPT | $117.81 0.59% 220K
|
Health Technology
|
| O: 0.0%
H: 0.25%
C: -2.43%
SGMO | News | $0.4922 -5.51% 700K
|
Health Technology
|
| O: -0.91%
H: 1.08%
C: -2.66%
RGNX | $15.75 -0.94% 120K
|
Health Technology
|
| O: -0.26%
H: 1.59%
C: -1.13%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 1.13%
H: 0.1%
C: -8.26%
NTLA | $21.1 -2.0% 360K
|
Health Technology
|
| O: -2.19%
H: 17.95%
C: 16.17%
GILD | $67.03 2.4M
|
Health Technology
|
| O: -0.04%
H: 0.53%
C: 0.38%
EDIT | News | $5.375 -1.56% 590K
|
Health Technology
|
| O: 2.07%
H: 3.99%
C: 2.67%
CRSP | News M | $56.02 -0.69% 390K
|
Health Technology
|
| O: -0.41%
H: 1.48%
C: -0.34%
BLUE | $0.9227 -4.94% 4.6M
|
Health Technology
|
| O: -0.26%
H: 0.64%
C: -3.25%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 1.49%
H: 0.0%
C: -2.44%
ALNY | $144.52 -1.06% 140K
|
Health Technology
|
| O: 0.42%
H: 0.15%
C: -0.62%
ADAP | $1.095 -3.95% 540K
|
Health Technology
|
| O: -0.68%
H: 1.6%
C: 0.23%
ABEO | News | $3.195 -6.31% 1.4M
|
Health Technology
|
| O: 0.0%
H: 0.59%
C: -2.96%
gene therapy therapy gene therapies market
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VIR | $8.205 0.92% 240K
|
Health Technology
|
| O: -0.52%
H: 1.36%
C: -7.74%
GILD | $67.03 2.4M
|
Health Technology
|
| O: -0.06%
H: 1.28%
C: 1.1%
ALNY | $144.52 -1.06% 140K
|
Health Technology
|
| O: 0.26%
H: 1.5%
C: 0.72%
hepatitis ongoing biotech technology iot liver trial injection infections chronic hepatitis b
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.